Skip to main content

Advertisement

Table 1 Demographic and baseline characteristics

From: Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: Latin American subpopulation analysis of a randomized trial

Characteristic LM25 (N = 80) IGL (N = 82) Total (N = 162)
Country, n (%)
 Argentina 40 (50.0) 39 (47.6) 79 (48.8)
 Brazil 20 (25.0) 23 (28.0) 43 (26.5)
 Mexico 20 (25.0) 20 (24.4) 40 (24.7)
Sex, n (%)
 Male 39 (48.8) 30 (36.6) 69 (42.6)
 Female 41 (51.3) 52 (63.4) 93 (57.4)
Age (years), mean (SD) 57.5 (9.7) 57.1 (8.4) 57.3 (9.0)
Weight (kg), mean (SD) 82.5 (15.4 81.8 (15.0) 82.2 (15.1)
BMI (kg/m2), mean (SD) 30.9 (4.8) 31.7 (5.5) 31.3 (5.2)
Duration of diabetes (years), mean (SD) 13.8 (7.9) 12.9 (6.8) 13.4 (7.3)
HbA1c at screening
 %, mean (SD) 8.8 (0.8) 8.6 (0.8) 8.7 (0.8)
 <8.5 %, n (%) 33 (41.3) 35 (42.7) 68 (42.0)
FPG (mg/dL), mean (SD) 107.1 (37.1) 98.5 (28.2) 102.8 (33.0)
Insulin glargine dose at screening (IU),  mean (SD) 39.3 (19.3) 39.5 (18.9) 39.4 (19.0)
Glycemic variability (mg/dL), mean (SD) 46.6 (18.8) 49.7 (18.6) 48.2 (18.7)
Concomitant oral antidiabetic drugs
 Metformin, n (%) 80 (100) 82 (100) 162 (100)
  Daily dose (mg), mean (SD) 1968.1 (393.0) 2062.8 (396.8) 2016.0 (396.6)
 Pioglitazone, n (%) 4 (5.0) 5 (6.1) 9 (5.6)
  Daily dose (mg), mean (SD) 30.0 (0.0) 30.0 (0.0) 30.0 (0.0)
 Metformin and pioglitazone, n (%) 4 (5.0) 5 (6.1) 9 (5.6)
  1. BMI body mass index, FPG fasting plasma glucose, HbA1c glycated hemoglobin, IGL once-daily basal insulin glargine plus once-daily prandial insulin lispro, IU international units, LM25 75 % insulin lispro protamine suspension and 25 % insulin lispro solution, SD standard deviation